Actinium PharmaceuticalsATNM
ATNM
About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Employees: 49
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
315% more call options, than puts
Call options by funds: $170K | Put options by funds: $41K
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
2.8% more ownership
Funds ownership: 24.4% [Q2] → 27.2% (+2.8%) [Q3]
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding
Funds holding: 72 [Q2] → 72 (+0) [Q3]
70% less capital invested
Capital invested by funds: $53.8M [Q2] → $15.9M (-$37.9M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
186%
upside
Avg. target
$4.50
221%
upside
High target
$5
257%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Stephens & Co. Sudan Loganathan 35% 1-year accuracy 7 / 20 met price target | 257%upside $5 | Overweight Reiterated | 19 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 117 / 398 met price target | 186%upside $4 | Buy Reiterated | 15 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 month ago
My Top 2 Stock Picks For A 2025 Rebound
Tax-loss selling and short-covering dynamics create January Effect Rally opportunities, particularly in small and mid-cap stocks. The AES Corporation is undervalued, offers a 5.4% dividend yield, and is poised to benefit from AI data center energy demand. Actinium Pharmaceuticals, Inc. is a high-risk, high-reward biotech with strong cash reserves, undervalued stock, and a promising cancer treatment pipeline.
Neutral
PRNewsWire
2 months ago
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha -particle emitting radioisotope, actinium-225, for potential cancer treatments The two sides aim to submit an Investigational New Drug application by 2027, in line with SK Biopharmaceuticals' roadmap to strengthen its radiopharmaceutical therapy business SK Biopharmaceuticals further accelerates the expansion of its radiopharmaceutical therapy pipeline and capability, via strengthened internal resources and partnerships SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea's premier research institution dedicated to the study and advancement of radiological and medical sciences, to collaborate on discovering and developing preclinical radiopharmaceutical drug candidates. This marks the first collaborative research agreement in which both sides will aim to discover radiopharmaceutical compounds and investigate novel oncological treatments, using actinium-225 (225Ac), an alpha-particle emitting radioisotope that selectively kills cancer cells.
Neutral
PRNewsWire
2 months ago
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed or refractory acute myeloid leukemia - Accomplished biopharma industry executive June Almenoff, M.D., Ph.D., appointed to Actinium's Board of Directors - Cash and cash equivalents of approximately $78.6 million as of September 30, 2024, is expected to fund operations into 2027 NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024.
Neutral
Accesswire
2 months ago
Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
PRNewsWire
2 months ago
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors.
Neutral
Accesswire
2 months ago
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
2 months ago
Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
2 months ago
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
2 months ago
Actinium Pharmaceuticals, Inc. Is Being Investigated For Violations Of Securities Laws And Affected Shareholders Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
2 months ago
The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Actinium Pharmaceuticals Inc For Fraud
LOS ANGELES, CA / ACCESSWIRE / October 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™